Data Sheet 1_Metachronous hepatocellular carcinoma after partial response of advanced intr

A 62-year-old male patient with occult HBV infection and stage IV intrahepatic cholangiocarcinoma with bone metastases was treated with radiotherapy followed by apatinib and camrelizumab, achieving partial remission. At 56-month follow-up, abdominal CT detected new hepatic lesions, which pathological examination confirmed as de novo hepatocellular carcinoma rather than iCCA recurrence. The case report, authored by Yujuan Dai and published on figshare under CC-BY-4.0 license, discusses diagnostic clues, pathogenesis, and therapeutic implications.

Use Cases

• Study diagnostic challenges in differentiating hepatocellular carcinoma from intrahepatic cholangiocarcinoma recurrence based on the described AFP-negative phenotype.
• Analyze treatment outcomes for advanced unresectable iCCA based on the described regimen of radiotherapy combined with anti-angiogenic and immunotherapy.
• Investigate potential pathogenesis links between occult HBV infection, chronic inflammation, liver radiotherapy, and multi-pathway hepatocarcinogenesis as discussed.
• Review the importance of active pathological biopsy for new hepatic lesions after iCCA remission to clarify diagnosis and guide treatment.

Strengths

• Provides detailed longitudinal clinical data for a single patient over a 56-month follow-up period.
• Includes specific treatment details (radiotherapy, apatinib, camrelizumab) and diagnostic results (CT, pathology, immunohistochemistry).
• Released under a permissive CC-BY-4.0 license, allowing for reuse and adaptation.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is contained within a 568.5 KB PDF file, which is a tiny dataset with limited scope.

Provenance

Source

Yujuan Dai via figshare.

Collection Method

Retrospective analysis of a single clinical case and review of relevant literature.

Time Range

Covers a patient's clinical course with a 56-month follow-up period.

Freshness

Last updated 2026-05-13 04:48:33; freshness should be verified.